EUVIMEDEUVIMED entdecken
Open Access

Temporally programmed STING nanoadjuvant delivery unlocks synergistic chemotherapy-induced antitumor immunity

Zimeng Yang iD, Hengzhi Liu, Shuo Li, Zhaochu Xu, Wenxiao Li, Yubo Liu, Qingzhi Lv, Hongzhuo Liu iD, Zhonggui He iD, Yongjun Wang iD

Science Advances · 18.07.2025 · 11 (29)

DOI: 10.1126/sciadv.adw0797 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 18.07.2025. Verfasst von Zimeng Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China. Hauptthemen laut MEDLINE: Membrane Proteins, Adjuvants, Immunologic, Antineoplastic Agents, Nanoparticles. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Stimulator of interferon genes (STING) agonists have attracted notable attention for their potent immune activation capabilities. However, their clinical application is hindered by systemic toxicity and delivery inefficiencies. We addressed these challenges by developing a lymph node–targeted STING agonist nanoadjuvant (Mn/MSA-2@Lipo) combined with a temporally optimized delivery strategy. Mn/MSA-2@Lipo uses manganese ions to amplify STING pathway activation while achieving efficient lymph node accumulation and antigen presentation. We first induced immunogenic cell death (ICD) through chemotherapy to release tumor antigens, followed by the administration of the nanoadjuvant at an optimized time interval, the approach effectively synchronizes dendritic cell (DC) antigen uptake and maturation. This combination therapy notably enhanced antitumor immunity in melanoma and breast cancer models, achieving complete tumor regression and inducing long-lasting immune memory, all while demonstrating an excellent safety profile. Our findings highlight the critical importance of delivery timing optimization, offering a promising strategy for the clinical translation of STING agonists and the design of advanced immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Membrane ProteinsAdjuvants, ImmunologicAntineoplastic AgentsNanoparticlesAnimalsMiceFemaleDendritic CellsCell Line, TumorHumansImmunotherapyImmunogenic Cell DeathMice, Inbred C57BLBreast NeoplasmsSTING Protein

Substanzen

Membrane ProteinsAdjuvants, ImmunologicAntineoplastic AgentsSting1 protein, mouseSTING Protein

Autor:innen und Institutionen

  • Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China.
  • School of Pharmacy, Binzhou Medical University, Yantai 264003, China.
  • Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China.

ORCID-Profile: Zimeng Yang, Hongzhuo Liu, Zhonggui He, Yongjun Wang

Zitieren

APA

Yang, Z., Liu, H., Li, S., Xu, Z., Li, W., Liu, Y., Lv, Q., Liu, H., He, Z., & Wang, Y. (2025). Temporally programmed STING nanoadjuvant delivery unlocks synergistic chemotherapy-induced antitumor immunity. Science Advances, 11(29). https://doi.org/10.1126/sciadv.adw0797

Vancouver

Yang Z, Liu H, Li S, Xu Z, Li W, Liu Y, et al. Temporally programmed STING nanoadjuvant delivery unlocks synergistic chemotherapy-induced antitumor immunity. Science Advances. 2025;11(29). doi:10.1126/sciadv.adw0797

BibTeX
@article{Yang2025,
  author = {Yang, Zimeng and Liu, Hengzhi and Li, Shuo and Xu, Zhaochu and Li, Wenxiao and Liu, Yubo and Lv, Qingzhi and Liu, Hongzhuo and He, Zhonggui and Wang, Yongjun},
  title = {Temporally programmed STING nanoadjuvant delivery unlocks synergistic chemotherapy-induced antitumor immunity},
  journal = {Science Advances},
  year = {2025},
  volume = {11},
  number = {29},
  doi = {10.1126/sciadv.adw0797}
}
Kostenlos starten →